Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Stopped early · Phase 3

Conditions studied: Gastrointestinal Stromal Tumor

In brief

A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or imatinib 800 mg daily. This study will find out the benefits and potential side effects of taking sunitinib or imatinib for approximately one year.

Key facts

Study ID

NCT00372567

Run by

Pfizer

People needed

69

Starts

2007-06-01

Expected to finish

2009-11-01

Last updated by the study team

2011-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with gastrointestinal stromal tumors whose disease has progressed on imatinib 400 mg daily.

You may not qualify if…

• Current treatment with any chemotherapy other than imatinib.
• Current treatment with any dose of imatinib other than 400 mg

Where it is running

• Pfizer Investigational Site — Detroit, Michigan, United States
• Pfizer Investigational Site — Farmington Hills, Michigan, United States
• Pfizer Investigational Site — City of Saint Peters, Missouri, United States
• Pfizer Investigational Site — Creve Coeur, Missouri, United States
• Pfizer Investigational Site — St Louis, Missouri, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Göttingen, Germany
• Pfizer Investigational Site — Hamburg, Germany
• Pfizer Investigational Site — Lai Chi Kok, Kowloon, Hong Kong
• Pfizer Investigational Site — Tuenmen, New Territories, Hong Kong
• Pfizer Investigational Site — Hong Kong, Hong Kong
• Pfizer Investigational Site — Bologna, Italy
• Pfizer Investigational Site — Milan, Italy
• Pfizer Investigational Site — San Giovanni Rotondo, Italy
• Pfizer Investigational Site — Seoul, South Korea
• Pfizer Investigational Site — Seoul, South Korea
• Pfizer Investigational Site — Seoul, South Korea
• Pfizer Investigational Site — Barcelona, Barcelona, Spain
• Pfizer Investigational Site — Valencia, Valencia, Spain
• Pfizer Investigational Site — Glasgow, United Kingdom
• Pfizer Investigational Site — Leeds, United Kingdom
• Pfizer Investigational Site — London, United Kingdom
• Pfizer Investigational Site — London, United Kingdom
• Pfizer Investigational Site — London, United Kingdom
• Pfizer Investigational Site — Manchester, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.